CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis
Author:
Affiliation:
1. Department of Geriatrics; West China Fourth Hospital, Sichuan University; Chengdu China
2. Xindu Hospital of Traditional Chinese Medicine; Chengdu China
3. Tibet University Medical College; Lasha China
Publisher
Wiley
Subject
Behavioral Neuroscience
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/brb3.1215/fullpdf
Reference20 articles.
1. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study;Bigal;The Lancet Neurology,2015
2. Blocking CGRP in migraine patients - a review of pros and cons;Deen;The Journal of Headache and Pain,2017
3. Migraines in women: Current evidence for management of episodic and chronic migraines;Deneris;Journal of Midwifery & Women's Health,2017
4. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study;Detke;Neurology,2018
5. Latin American consensus on guidelines for chronic migraine treatment;Giacomozzi;Arquivos De Neuro-Psiquiatria,2013
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Systemic allergic reaction to galcanezumab (emgality): a case report;Cephalalgia;2024-01
2. Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clinical and genetic study;Headache: The Journal of Head and Face Pain;2023-12-10
3. Migraine headache: When to consider these newer agents;The Journal of Family Practice;2023-09
4. Az adenilát-cikláz-aktiváló polipeptid (PACAP) klinikai jelentősége;Orvosi Hetilap;2023-08-20
5. Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study;Cephalalgia;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3